Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
ABCC4 10257 THIOGUANINE CHEMBL727 NCI 14643890
ABCC4 10257 GANCICLOVIR CHEMBL182 NCI 12105214
ABCC4 10257 MEDRONIC ACID CHEMBL180570 PharmGKB
ABCC4 10257 LAMIVUDINE CHEMBL141 PharmGKB
ABCC4 10257 CYCLOPHOSPHAMIDE CHEMBL88 PharmGKB
ABCC4 10257 ESTRADIOL DISULFATE CHEMBL1162492 inhibitor GuideToPharmacologyInteractions
ABCC4 10257 ADEFOVIR CHEMBL484 NCI 10470083, 12695538
ABCC4 10257 INDINAVIR CHEMBL115 PharmGKB
ABCC4 10257 MERCAPTOPURINE CHEMBL1425 PharmGKB
ABCC4 10257 ZIDOVUDINE CHEMBL129 PharmGKB, NCI 12105214
ABCC4 10257 FLUOROURACIL CHEMBL185 PharmGKB
ABCC4 10257 LEUCOVORIN CHEMBL1679 NCI 12036927
ABCC4 10257 METHOTREXATE CHEMBL34259 NCI 12036927

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
ABCC4 rs9516519 G methotrexate metabolism/PK no All patients received four cycles of high dose MTX (5000mg per square meter of body surface area). 1/10th of the dose was administered over 30 minutes (rapid infusion) and the rest was administered continuously over 24hrs. Leucovorin rescue was administered every 6hrs starting 48 hrs after initiation of MTX infusion. Allele G is not associated with clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T. 24404132 1184175529
ABCC4 rs2274407 A methotrexate metabolism/PK no All patients received four cycles of high dose MTX (5000mg per square meter of body surface area). 1/10th of the dose was administered over 30 minutes (rapid infusion) and the rest was administered continuously over 24hrs. Leucovorin rescue was administered every 6hrs starting 48 hrs after initiation of MTX infusion. Allele A is not associated with clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele C. 24404132 1184175533
ABCC4 rs868853 C methotrexate metabolism/PK no All patients received four cycles of high dose MTX (5000mg per square meter of body surface area). 1/10th of the dose was administered over 30 minutes (rapid infusion) and the rest was administered continuously over 24hrs. Leucovorin rescue was administered every 6hrs starting 48 hrs after initiation of MTX infusion. Allele C is not associated with clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T. 24404132 1184175537
ABCC4 rs3765534 TT mercaptopurine dosage no This was not significant when looking at each variant individually but was significant when looking at the set of homozygous minor allele variants for the three ABCC4 SNPs ( G2269A (rs3765534), C912A (rs2274407), and G559T (rs11568658)) in ITPA major allele homozygotes. Genotype TT is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT. 25403995 1448602706
ABCC4 rs2274407 AA mercaptopurine dosage yes This was borderline significant significant for this variant individually but was significant when looking at the set of homozygous minor allele variants for the three ABCG2 SNPs ( G2269A (rs3765534), C912A (rs2274407), and G559T (rs11568658)) in ITPA major allele homozygotes. Genotype AA is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AC + CC. 25403995 1448602719
ABCC4 rs11568658 AA mercaptopurine dosage no This was not significant when looking at each variant individually but was significant when looking at the set of homozygous minor allele variants for the three ABCC4 SNPs ( G2269A (rs3765534), C912A (rs2274407), and G559T (rs11568658)) in ITPA major allele homozygotes. Genotype AA is associated with decreased dose of mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AC + CC. 25403995 1448602730
ABCC4 rs1751034 TT tenofovir metabolism/PK not stated Authors stated" Patients carrying ABCC4 3463 AG or GG had a tenofovir CL/F 11% higher than those with genotype AA." Allele complemented to plus chromosomal strand. Genotype TT is associated with decreased clearance of tenofovir in people with HIV Infections as compared to genotypes CC + CT. 29061086 1449004578
ABCC4 rs1751034 CC + CT tenofovir metabolism/PK no Genotypes CC + CT is not associated with concentrations of tenofovir in people with HIV Infections as compared to genotype TT. 25801567 1444703303
ABCC4 rs3742106 AC + CC tenofovir metabolism/PK yes Patients with ABCC4 4131 TG or GG genotype had a 30% increase of mean tenofovir plasma concentration. Genotypes AC + CC is associated with increased concentrations of tenofovir in people with HIV Infections as compared to genotype AA. 25801567 1444703265
ABCC4 rs899494 AA + AG tenofovir toxicity no Genotypes AA + AG is not associated with increased discontinuation of tenofovir in people with HIV Infections as compared to genotype GG. 21288825 1184747485
ABCC4 rs9561765 AG imatinib efficacy yes Patients with the AG genotype had prolonged time to progression, which was calculated from the start of therapy to the date of disease progression as documented by a CT scan performed every 3-4 months. Genotype AG is associated with increased response to imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype AA. 23127916 982046742
ABCC4 rs11568668 TT latanoprost efficacy no Primary outcome was % change in intraocular pressure (%delta IOP). % delta IOP= ((Baseline IOP values - IOP values posttreatment) / Baseline IOP values × 100 %.) Genotype TT is not associated with response to latanoprost in people with Glaucoma, Open-Angle as compared to genotypes CC + CT. 25339146 1296666938
ABCC4 rs11568658 AC latanoprost efficacy yes Primary outcome was % change in intraocular pressure (%delta IOP). % delta IOP= ((Baseline IOP values - IOP values posttreatment) / Baseline IOP values × 100 %.) Genotype AC is associated with decreased response to latanoprost in people with Glaucoma, Open-Angle as compared to genotype CC. 25339146 1296666927
ABCC4 rs9561778 GG cyclophosphamide "efficacy","toxicity","metabolism/PK" no Genotype GG is not associated with increased response to cyclophosphamide in people with Lupus Nephritis as compared to genotypes GT + TT. 26222310 1447676175
ABCC4 rs146708960 CT mercaptopurine dosage no Genotype CT is not associated with dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC. 29683944 1449311146
ABCC4 rs3765534 CC mercaptopurine dosage no Genotype CC is not associated with dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CT. 29683944 1449311123
ABCC4 rs9516519 G methotrexate metabolism/PK no Please note that alleles have been complemented to the positive strand. Allele G is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele T. 29791011 1450045109
ABCC4 rs17268282 T furosemide efficacy yes Decompensated heart failure. Meta-analysis of the DOSE, CARRESS and ROSE randomized trials. Carriers of the T allele experienced a greater amount of weight loss, and therefore an increased response to furosemide, as compared to those with the G allele. No association was seen between this variant and net fluid loss (p=0.12). Please note that alleles have been complemented to the plus chromosomal strand. Allele T is associated with increased response to furosemide in people with Heart Failure as compared to allele G. 26927285 1448424016